AbbVie (North Chicago, IL) has agreed to acquire Allergan (Dublin, Ireland) for a transaction equity value of approximately $63 billion. AbbVie will pay $188.24 for each share of Allergan, made up of $120.30 in the form of cash and the rest in stock. The combined company will consist of several attractive franchises with leadership positions across immunology, hematologic oncology, medical aesthetics, neuroscience, women's health, eye care and virology, with Allergan's product portfolio enhanced by AbbVie's commercial strength, expertise and international infrastructure, the companies reported in a press statement. "With 2019 annual combined revenue of approximately $48 billion, scale in more than 175 countries, an industry-leading R&D pipeline and robust cash flows, our combined company will have the opportunity to make even bigger contributions to global health than either can alone," said Brent Saunders, chairman and CEO, Allergan. "Our fast-growing therapeutic areas, including our world class medical aesthetics, eye care, CNS and gastrointestinal businesses, will enhance AbbVie's strong growth platform and create substantial value for shareholders of both companies." Upon completion of the transaction, AbbVie will continue to be incorporated in Delaware as AbbVie Inc. and have its principal executive offices in North Chicago, IL. The company will continue to be led by Richard A. Gonzalez as chairman and CEO. Two members of Allergan's Board, Saunders, will join AbbVie's Board.
The Misinformation Maze: Navigating Public Health in the Digital Age
March 11th 2025Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.
The 8 Market Access Performance Metrics You Should Be Tracking
March 25th 2025This guide offers an in-depth analysis of the essential KPIs that market access teams should track to measure success particularly across speed of access, breadth of access, and price performance. It includes real-life use cases and practical steps on how to get started.